



**Statement of stand-alone Financial Results for the quarter ended 30<sup>th</sup> September, 2013**

Rs. lakhs

<b>PART I : STATEMENT OF STAND-ALONE RESULTS</b>						
<b>PARTICULARS</b>	<b>THREE MONTHS ENDED (REVIEWED)</b>			<b>YEAR-TO-DATE FIGURES (REVIEWED) FOR THE HALF YEAR ENDED ON</b>		<b>YEAR ENDED (AUDITED)</b>
	<b>30-SEP-2013</b>	<b>30-JUN-2013</b>	<b>30-SEP-2012</b>	<b>30-SEP-2013</b>	<b>30-SEP-2012</b>	<b>31-MAR-2013</b>
01. Gross Sales / Income from Operations	14019	14254	15669	28273	27332	54656
Less : Excise Duty	375	291	701	666	1179	2122
Less : Sales Tax	269	278	267	547	594	1101
Net Sales / Income from Operations	13375	13685	14701	27060	25559	51433
02. Other Operating Income	1631	797	501	2428	1005	4492
<b>03. TOTAL INCOME FROM OPERATIONS</b>	<b>15006</b>	<b>14482</b>	<b>15202</b>	<b>29488</b>	<b>26564</b>	<b>55925</b>
<b>04. EXPENDITURE</b>						
a) Cost of materials consumed	3755	3871	3786	7626	8225	18063
b) Purchases of stock-in-trade	-	-	238	-	432	558
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-227	-275	481	-502	-908	-2125
d) Employee benefits expense	2214	2205	2643	4419	4571	8536
e) Depreciation and amortization expense	656	641	466	1297	898	1984
f) Other Expenses	4601	4172	3385	8773	6693	15201
<b>TOTAL EXPENSES</b>	<b>10999</b>	<b>10614</b>	<b>10999</b>	<b>21613</b>	<b>19911</b>	<b>42217</b>
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	4007	3868	4203	7875	6653	13708
06. Other Income	177	350	120	527	421	1194
07. Finance costs	957	958	567	1915	1011	2512
08. Exceptional Items	-	-	618	-	618	1158
09. Profit / (Loss) from ordinary activities before tax	3227	3260	3138	6487	5445	11232
10. Tax expense, including deferred tax	358	986	751	1344	1241	3419
11. Net Profit / Loss (-) from ordinary activities after tax	2869	2274	2387	5143	4204	7813
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137	3115	3137
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						50621
14. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.) - non-annualized	9.15 9.15	7.25 7.25	7.66 7.61	16.40 16.40	13.50 13.40	25.02 24.91
<b>PART II : SELECT INFORMATION</b>						
15. Public Shareholding:						
a) Number of Shares	13,611,493	13,607,593	13,378,071	13,611,493	13,378,071	13,594,593
b) Percentage of Shareholding	43.39	43.37	42.95	43.39	42.95	43.33
16. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered -	-	-	-	-	-	-
b) Non - encumbered - No. of shares	17,761,581	17,765,481	17,769,881	17,761,581	17,769,881	17,778,481
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.61	56.63	57.05	56.61	57.05	56.67

Dated at Hyderabad, this, the 14<sup>th</sup> day of November, 2013.  
for and on behalf of the Board of Directors,  
**NATCO Pharma Limited**

V.C. Nannapaneni  
Chairman & Managing Director

Status of Investor Complaints as at 30th September, 2013

Pending as on 01-07-2013	Nil
Received during the quarter	52
Resolved during the quarter	52
Pending as on 30-09-2013	Nil

<b>Statement of Stand-alone Assets &amp; Liabilities (Rs. Lakhs)</b>		
	<b>As at</b>	
	<b>30 September 2013</b>	<b>31 March 2013</b>
	<b>Un-audited</b>	<b>Audited</b>
<b>I. Equity and liabilities</b>		
<b><i>Shareholders' funds</i></b>		
Share capital	3,137	3,137
Reserves and surplus	55,877	50,621
	<b>59,014</b>	<b>53,758</b>
<b><i>Non-current liabilities</i></b>		
Long-term borrowings	13,157	13,713
Deferred tax liabilities (net)	4,080	4,112
Other long term liabilities	69	69
Long-term provisions	948	821
	<b>18,254</b>	<b>18,715</b>
<b><i>Current liabilities</i></b>		
Short-term borrowings	16,794	14,774
Trade payables	9,808	10,443
Other current liabilities	10,153	8,025
Short-term provisions	33	33
	<b>36,788</b>	<b>33,275</b>
<b>Total</b>	<b>114,056</b>	<b>105,748</b>
<b>II. Assets</b>		
<b><i>Non-current assets</i></b>		
Fixed assets		
Tangible assets	48,658	46,565
Intangible assets	482	491
Capital work-in-progress	10,238	7,837
Non-current investments	7,830	7,676
Long-term loans and advances	11,925	12,066
Other non-current assets	-	13
	<b>79,133</b>	<b>74,648</b>
<b><i>Current assets</i></b>		
Current investments	81	81
Inventories	13,549	12,832
Trade receivables	14,890	12,646
Cash and bank balances	1,142	937
Short-term loans and advances	4,911	4,269
Other current assets	350	335
	<b>34,923</b>	<b>31,100</b>
	<b>114,056</b>	<b>105,748</b>





**Statement of consolidated Financial Results for the quarter ended 30<sup>th</sup> September, 2013**

Rs. lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR-TO-DATE FIGURES (UNREVIEWED/UNAUDITED) FOR THE HALF YEAR ENDED ON		YEAR ENDED (AUDITED)	
	PARTICULARS (REFER NOTES BELOW)	30-SEP-2013	30-JUN-2013	30-SEP-2012	30-SEP-2013	30-SEP-2012	31-MAR-2013
01. Gross Sales / Income from Operations	16952	17062	17890	34014	32612	65302	
Less : Excise Duty	390	323	707	713	1185	2122	
Less : Sales Tax	271	285	267	556	594	1101	
Net Sales / Income from Operations	16291	16454	16916	32745	30833	62079	
02. Other Operating Income	1631	797	1116	2428	1271	4322	
03. TOTAL INCOME FROM OPERATIONS	17922	17251	18032	35173	32104	66401	
04. EXPENDITURE							
a) Cost of materials consumed	6013	5745	5939	11758	12451	17757	
b) Purchases of stock-in-trade	-	-	238	-	432	8714	
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-227	-275	481	-502	-908	-2191	
d) Employee benefits expense	2633	2589	3100	5222	5243	10229	
e) Depreciation and amortization expense	747	731	510	1478	953	2212	
f) Other Expenses	5155	4724	3921	9879	7646	16900	
TOTAL EXPENSES	14321	13514	14189	27835	25817	53621	
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3601	3737	3843	7338	6287	12780	
06. Other Income	198	350	88	548	266	1241	
07. Finance costs	1002	996	583	1998	1050	2631	
08. Exceptional Item	-	-	618	-	618	1158	
09. Profit / (Loss) from ordinary activities before tax	2797	3091	2730	5888	4885	10232	
10. Tax expense, including deferred tax	371	1014	771	1385	1262	3644	
11. Minority Interest	266	101	-140	367	-172	-599	
12. Net Profit / Loss (-) from ordinary activities after tax	2692	2178	2099	4870	3795	7187	
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137	3115	3137	
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						50217	
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	8.58	6.94	6.74	15.52	12.18	23.01	
	8.58	6.94	6.71	15.52	12.16	22.91	
<b>PART II : SELECT INFORMATION</b>							
16. Public Shareholding:							
a) Number of Shares	13,611,493	13,607,593	13,378,071	13,611,493	13,378,071	13,594,593	
b) Percentage of Shareholding	43.39	43.37	42.95	43.39	42.95	43.33	
16. Promoters and Promoter Group Shareholding							
a) Pledged / Encumbered – No. of shares	-	-	-	-	-	-	
b) Non – encumbered – No. of shares	17,761,581	17,765,481	17,769,881	17,761,581	17,769,881	17,778,481	
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	
Percentage (as a % of the total share capital of the company)	56.61	56.63	57.05	56.61	57.05	56.67	

The above financial results were approved by the Audit Committee and the Board of Directors at a meeting held at Hyderabad on Thursday, the 14<sup>th</sup> November, 2013. Exceptional item represents amount written off against a pending legal dispute. Employee benefit expenses for the quarter and six months ended 30<sup>th</sup> September, 2012 include Rs. 504 lakhs and Rs. 362 lakhs respectively, pertaining to stock options vested during the earlier period. The stand-alone results are available on the company's web-site [www.natcopharma.co.in](http://www.natcopharma.co.in). In respect of reference to relating to non-accounting of minimum alternate tax credit, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 14<sup>th</sup> November, 2013.  
for and on behalf of the Board of Directors,  
**NATCO** Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director

Status of Investor Complaints as at 30th September, 2013

Pending as on 01-07-2013	Nil
Received during the quarter	52
Resolved during the quarter	52
Pending as on 30-09-2013	Nil

<b>Statement of Consolidated Assets &amp; Liabilities (Rs. Lakhs)</b>		
	<b>As at</b>	
	<b>30 September 2013</b>	<b>31 March 2013</b>
<b>I. Equity and liabilities</b>		
<b><i>Shareholders' funds</i></b>		
Share capital	6,818	3,137
Reserves and surplus	54,202	50,217
	<b>61,020</b>	<b>53,354</b>
<b><i>Non-current liabilities</i></b>		
Long-term borrowings	13,171	13,783
Deferred tax liabilities (net)	4,316	4,432
Other long term liabilities	6,092	1,123
Long-term provisions	1,614	862
	<b>25,193</b>	<b>20,200</b>
<b><i>Current liabilities</i></b>		
Short-term borrowings	16,979	14,774
Trade payables	10,703	11,430
Other current liabilities	10,768	8,177
Short-term provisions	33	107
	<b>38,483</b>	<b>34,488</b>
<b>Total</b>	<b>125,155</b>	<b>108,042</b>
<b>II. Assets</b>		
<b><i>Non-current assets</i></b>		
Fixed assets		
Tangible assets	53,129	55,390
Intangible assets	2,586	2,884
Capital work-in-progress	11,726	10,584
Non-current investments	7,830	154
Long-term loans and advances	11,941	5,720
Other non-current assets	0	13
	<b>87,212</b>	<b>74,745</b>
<b><i>Current assets</i></b>		
Current investments	81	81
Inventories	15,069	14,603
Trade receivables	15,540	12,971
Cash and bank balances	1,453	1,265
Short-term loans and advances	5,305	4,041
Other current assets	496	336
	<b>37,944</b>	<b>33,297</b>
<b>Total</b>	<b>125,155</b>	<b>108,042</b>





**Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter ended on 30<sup>th</sup> September, 2013**

*Rs. lakhs*

	THREE MONTHS ENDED			HALF YEAR ENDED		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED) 31-MAR-2013
	30-SEP-2013	30-JUN-2013	30-SEP-2012	30-SEP-2013	30-SEP-2012	
<b>01. Segment Revenue (Net)</b>						
a) Bulk Chemicals	5570	6370	6417	11940	10387	23692
b) Formulations	9616	6488	7758	16104	14814	29367
c) Job Work	418	195	314	613	470	944
d) Unallocated	38	1841	940	1879	1599	3244
<b>Total</b>	<b>15642</b>	<b>14894</b>	<b>15429</b>	<b>30536</b>	<b>27270</b>	<b>57247</b>
<b>Less : Inter-segment Revenue</b>	636	412	227	1048	706	1322
<b>Net Sales / Income from Operations</b>	<b>15006</b>	<b>14482</b>	<b>15202</b>	<b>29488</b>	<b>26564</b>	<b>55925</b>
<b>02. Segment Results : Profit (+)/Loss (-) before tax and interest</b>						
a) Bulk Chemicals	1051	1517	1719	2568	2372	5527
b) Formulations	4474	2186	3643	6660	6568	12235
c) Job Work	332	139	275	471	391	728
d) Unallocated	21	1673	849	1694	1440	2915
<b>Total</b>	<b>5878</b>	<b>5515</b>	<b>6486</b>	<b>11393</b>	<b>10771</b>	<b>21405</b>
<b>Less : a) Interest</b>	957	958	567	1915	1011	2512
<b>b) Oher unallocable expenditure</b>	1871	1647	2901	3518	4736	8855
<b>c) Unallocable income</b>	177	350	120	527	421	1194
<b>Total Profit Before Tax</b>	<b>3227</b>	<b>3260</b>	<b>3138</b>	<b>6487</b>	<b>5445</b>	<b>11232</b>
<b>03. Capital Employed (Segment Assets - Segment Liabilities)</b>						
a) Bulk Chemicals	37017	37370	36456	37017	36456	36375
b) Formulations	35170	30873	30617	35170	30617	32742
c) Job Work	295	156	172	295	172	94
e) Unallocated (Others)	-13468	-12367	-15695	-13468	-15695	-15453
<b>Total</b>	<b>59014</b>	<b>56032</b>	<b>51550</b>	<b>59014</b>	<b>51550</b>	<b>53758</b>

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 14<sup>th</sup> November, 2013. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Exceptional item represents amount written off against a pending legal dispute. Employee benefit expenses for the quarter and six months ended 30 September 2012 include Rs. 504 lakhs and Rs. 362 lakhs respectively, pertaining to stock options vested during the earlier period.

Dated at Hyderabad, this, the 14<sup>TH</sup> day of November, 2013.

for and on behalf of the Board of Directors,

**NATCO Pharma Limited**

V.C. Nannapaneni  
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.  
Tel : +91 40 23547532, Fax : +91 40 23548243

### PRESS RELEASE

14<sup>th</sup> November, 2013

#### NATCO records higher profits

Hyderabad based NATCO Pharma Limited has recorded higher profits for the quarter ended 30<sup>th</sup> September, 2013.

For the quarter ended 30<sup>th</sup> September, 2013, on a consolidated revenue base of Rs. 188 Crores, the company earned a net profit after tax, of Rs. 27 Crores as against Rs. 21 Crores on a revenue base of Rs. 191 Crores last year.

The EBIDTA margins have expanded to 31% of the revenues, from 26% last year.

The growth has been driven by value-added formulation exports during the quarter.

---

#### Forwarded for favour of publication

**For NATCO Pharma Limited**

*M Adinarayana*

**M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp. Affairs)**